50479-11-3

Usage

Uses

Used in Pharmaceutical Industry:
[3-(ETHOXYCARBONYL)PROPYL]TRIPHENYLPHOSPHONIUM BROMIDE is used as a reactant for the asymmetric synthesis of antihypercholesterolemic ezetimibe. Its unique structure allows for the selective formation of desired chiral products, which is crucial in the development of effective and safe pharmaceuticals.
Used in Chemical Synthesis:
In the field of organic chemistry, [3-(ETHOXYCARBONYL)PROPYL]TRIPHENYLPHOSPHONIUM BROMIDE is used as a reactant in Wittig reactions. These reactions are essential for the synthesis of various complex organic molecules, including pharmaceuticals, agrochemicals, and natural products. [3-(ETHOXYCARBONYL)PROPYL]TRIPHENYLPHOSPHONIUM BROMIDE's ability to participate in these reactions makes it a valuable tool in the synthesis of a wide range of molecules.
Overall, [3-(ETHOXYCARBONYL)PROPYL]TRIPHENYLPHOSPHONIUM BROMIDE is a versatile compound with applications in both the pharmaceutical and chemical synthesis industries, primarily due to its unique structure and reactivity in various chemical processes.

InChI:InChI=1/C24H26O2P.BrH/c1-2-26-24(25)19-12-20-27(21-13-6-3-7-14-21,22-15-8-4-9-16-22)23-17-10-5-11-18-23;/h3-11,13-18H,2,12,19-20H2,1H3;1H/q+1;/p-1

Upstream product

• 2969-81-5 Ethyl 4-bromobutyrate 
• 603-35-0 triphenylphosphine 
• 64-17-5 ethanol 
• 17857-14-6 (3-carboxypropyl)(triphenyl)phosphonium bromide 

Downstream Products

• 7367-84-2 (Z)-4-decenoic acid ethyl ester 
• 161040-07-9 ethyl (4Z,6S)-6-<(tert-butyldiphenylsilyl)oxy>-4-heptenoate 
• 161040-08-0 (Z)-(S)-6-Benzyloxymethoxy-hept-4-enoic acid ethyl ester 
• 161040-09-1 (Z)-(S)-6-(tert-Butyl-diphenyl-silanyloxy)-non-4-enoic acid ethyl ester 
• 121746-04-1 ethyl (4Z)-5-phenyl-4-pentenoate 
• 934400-55-2 C₃₃H₄₉NO₅Si 
• 928-91-6 (Z)-4-hexenol 
• 4634-89-3 cis-hex-4-enal 
• 127391-16-6 3-[(2R,3S)-3-((1R,2R)-3-Benzyloxycarbonylamino-1,2-dihydroxy-propyl)-oxiranyl]-propionic acid ethyl ester 
• 127391-18-8 (R)-4-Bromo-4-[(3aS,4R,6aR)-2,2-dimethyl-5-(toluene-4-sulfonyl)-tetrahydro-[1,3]dioxolo[4,5-c]pyrrol-4-yl]-butyric acid ethyl ester 
• 127391-14-4 3-{(2R,3R)-3-[(4R,5R)-5-(Benzyloxycarbonylamino-methyl)-2,2-dimethyl-[1,3]dioxolan-4-yl]-oxiranyl}-propionic acid ethyl ester 
• 127391-15-5 3-{(2S,3S)-3-[(4R,5R)-5-(Benzyloxycarbonylamino-methyl)-2,2-dimethyl-[1,3]dioxolan-4-yl]-oxiranyl}-propionic acid ethyl ester 
• 5648-17-9 4-(bicyclo[2.2.1]heptan-2-ylidene)butanoic acid 
• 1393706-29-0 (E)-ethyl 5-(p-methoxyphenyl)-hex-4-enoate 

Relevant academic research and scientific papers

Annulations via dianions: Formation of five-, six- and seven-membered rings

Phosphonium salts bearing an electron-withdrawing group at the γ-position form dianions that react with bis-electrophiles to generate five-, six-, and seven- membered rings.

Phosphatidylcholine bearing 6,6-dideuterated oleic acid: A useful solid-state 2H NMR probe for investigating membrane properties

Lipid organization has been at the center of research on lipid rafts. Dioleoylphosphatidylcholine (DOPC) is a typical unsaturated lipid. Very few studies have reported its thermodynamics in raft-like membranes. Herein, we have developed a highly efficient

Sulfonamide hapten, sulfonamide artificial antigen and their preparation methods and application

The invention relates to a sulfonamide hapten, a sulfonamide artificial antigen and their preparation methods and application. The sulfonamide hapten has a structure shown as formula (1) which is shown in the description, wherein n is an integer equal to 0, or greater than and equal to 1. The sulfonamide artificial antigen is made by coupling the hapten of the formula (1) and a carrier protein. Byimmunizing animals with the sulfonamide artificial antigen, specific antibodies with high efficacy and high sensitivity can be attained. The sulfonamide hapten and antibodies prepared with the same help provide a new means to establish a method to detect sulfonamides under high speed, good simplicity, low cost, good sensitivity and good specificity.

Chiral Phosphoric-Acid-Catalyzed Cascade Prins Cyclization

Asymmetric Prins cyclization of in situ generated quinone methides and o-aminobenzaldehyde has been developed with chiral phosphoric acid as an efficient catalyst. This unconventional method provides a facile access to diverse functionalized trans-fused pyrano-/furo-tetrahydroquinoline derivatives in excellent yield and with excellent diastereo- and enantioselectivities (up to 99% yield and 99% ee). Mechanistic studies suggested that the three adjacent tertiary stereocenters were constructed through the sequential formation of C-O, C-C, and C-N bonds.

Synthesis of 1-Acyl-2-vinylcyclopropanes: Utilizing Copper-Carbenoid versus Sulfur Ylide Methodology

The synthesis of a range of racemic 1-acyl-2-vinylcyclopropanes by using two different methodologies is studied. We have developed a copper-catalyzed process for converting diazoketones into 1-acyl-2-vinylcyclopropanes and a sulfur-ylide-mediated procedur

Iron-Nickel Dual-Catalysis: A New Engine for Olefin Functionalization and the Formation of Quaternary Centers

Alkene hydroarylation forms carbon-carbon bonds between two foundational building blocks of organic chemistry: olefins and aromatic rings. In the absence of electronic bias or directing groups, only the Friedel-Crafts reaction allows arenes to engage alkenes with Markovnikov selectivity to generate quaternary carbons. However, the intermediacy of carbocations precludes the use of electron-deficient arenes, including Lewis basic heterocycles. Here we report a highly Markovnikov-selective, dual-catalytic olefin hydroarylation that tolerates arenes and heteroarenes of any electronic character. Hydrogen atom transfer controls the formation of branched products and arene halogenation specifies attachment points on the aromatic ring. Mono-, di-, tri-, and tetra-substituted alkenes yield Markovnikov products including quaternary carbons within nonstrained rings.

Dirhodium(II)-Mediated Alkene Epoxidation with Iodine(III) Oxidants

Dirhodium(II) complexes and iodine(III) oxidants have found useful applications in synthetic nitrene chemistry. In this study, the combination of the dirhodium(II) complex Rh2(tpa)4 (tpa = triphenylacetate) with the iodine(III) oxidant PhI(OPiv)2 is shown to promote the epoxidation of alkenes in the presence of 2 equivalents of water. The reaction can be applied to diversely substituted alkenes and the corresponding epoxides are isolated with yields of up to 90 %. A possible mechanism involves the dirhodium(II) complex as a Lewis acid species that would tune the oxidizing character of the iodine(III) reagent.

trans-Cyclooctenes as Halolactonization Catalysts

The strained olefins in trans-cyclooctenes serve as efficient catalysts for halolactonizations, including bromolactonizations and iodolactonizations. The trans-cyclooctene framework is essential for excellent catalytic performance, and the substituents also play important roles in determining efficiency. These results are the first demonstration of catalysis by a trans-cyclooctene.

The compound, composition, and display device

PROBLEM TO BE SOLVED: To provide a compound capable of elevating an upper limit temperature where a SmC (smectic-C) phase of a liquid crystal can exist, broadening a temperature width of the SmC phase or enlarging a tilt angle of the SmC phase, and to provide a liquid crystal composition comprising the compound and a display element including the liquid crystal composition.SOLUTION: [1] The compound is expressed by general formula (i) shown below. In general formula (i), R and R' each independently represent a hydrogen atom, an alkyl group having 1 to 10 carbon atoms, or an alkoxy group having 1 to 9 carbon atoms; A1, A2 and A3 each independently represent a 1,4-phenylene group or a 2,3-difluoro-1,4-phenylene group; m represents an integer of 1 to 10; and Y represents a cyclohexylene group, a phenylene group, a bicyclooctylene group or a dialkylsilylene group.

NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF

A compound of the Formula (I) is disclosed: (I) or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification. Also described are a pharmaceutical composition comprising the same and a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, lung, and liver, and kindey diseases, and hair loss using the same.